|
Market Closed -
Nasdaq
23:00:00 02/10/2026 +03
|
5-day change | 1st Jan Change | ||
| 14.99 USD | +0.27% |
|
-3.10% | -17.46% |
| 09-21 | Avalo Therapeutics, Inc.(NasdaqCM:AVTX) added to S&P Global BMI Index | CI |
| 08-19 | Avalo Therapeutics Insider Sold Shares Worth $1,450,419, According to a Recent SEC Filing | MT |
Company Valuation: Avalo Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 190.9 | 47.45 | 7.295 | 77.74 | 329.3 | 803.9 | - | - |
| Change | - | -75.15% | -84.63% | 965.79% | 323.58% | 144.12% | - | - |
| Enterprise Value (EV) 1 | 190.9 | 47.45 | 7.295 | 77.74 | 231 | 379.9 | 498.4 | 377.1 |
| Change | - | -75.15% | -84.63% | 965.79% | 197.1% | 64.48% | 31.18% | -24.33% |
| P/E | -2.05x | -1.14x | -0.08x | -0.94x | -3.11x | -5.29x | -5.46x | -5.7x |
| PBR | - | - | - | - | - | - | - | - |
| PEG | - | 0x | 0x | 0x | 0.1x | 0.1x | 1.76x | 1.35x |
| Capitalization / Revenue | 35.4x | 2.63x | 3.79x | 176x | 5,582x | - | - | - |
| EV / Revenue | 35.4x | 2.63x | 3.79x | 176x | 3,915x | - | - | - |
| EV / EBITDA | - | - | - | - | - | -3.92x | -3.75x | - |
| EV / EBIT | -2.32x | -1.27x | -0.27x | -1.13x | -3.17x | -3.46x | -3.74x | -2.66x |
| EV / FCF | -2.69x | -1.77x | - | -1.58x | -4.49x | -4.63x | -4.41x | -2.73x |
| FCF Yield | -37.2% | -56.6% | - | -63.1% | -22.3% | -21.6% | -22.7% | -36.6% |
| Dividend per Share 2 | - | - | - | - | - | 0.0114 | 0.00075 | - |
| Rate of return | - | - | - | - | - | 0.08% | 0.01% | - |
| EPS 2 | -2,390 | -1,063 | -114 | -7.94 | -5.84 | -2.835 | -2.748 | -2.632 |
| Distribution rate | - | - | - | - | - | -0.4% | -0.03% | - |
| Net sales 1 | 5.398 | 18.05 | 1.924 | 0.441 | 0.059 | - | - | - |
| EBITDA 1 | - | - | - | - | - | -96.92 | -132.7 | - |
| EBIT 1 | -82.13 | -37.44 | -27.35 | -68.51 | -72.92 | -109.8 | -133.3 | -141.9 |
| Net income 1 | -84.38 | -41.66 | -31.54 | -35.13 | -78.26 | -111.2 | -132.5 | -155.9 |
| Net Debt 1 | - | - | - | - | -98.34 | -424 | -305.6 | -426.8 |
| Reference price 2 | 4,895.96 | 1,209.61 | 9.10 | 7.43 | 18.16 | 14.99 | 14.99 | 14.99 |
| Nbr of stocks (in thousands) | 39 | 39.2 | 802 | 10,464 | 18,134 | 53,630 | - | - |
| Announcement Date | 3/2/22 A | 3/29/23 A | 3/29/24 A | 3/20/25 A | 3/23/26 A | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -5.29x | - | -3.92x | - | 804M | |
| 21.73x | 7.71x | 15.48x | 1.37% | 74.16B | |
| 29.82x | 8.57x | 26.7x | 0.04% | 57.39B | |
| 32.98x | 5.93x | 17.77x | 0.98% | 47.64B | |
| -21.31x | 230.81x | -22.97x | -.--% | 44.29B | |
| 33.26x | 3.23x | 13.97x | -.--% | 42.5B | |
| 46.77x | 5.41x | 29.66x | -.--% | 40.71B | |
| 27.63x | 7.93x | 20.48x | 0.41% | 30.97B | |
| 32.99x | 7.05x | 18.3x | -.--% | 28.53B | |
| -15.1x | 5.68x | -7.14x | -.--% | 24.34B | |
| Average | 18.35x | 31.37x | 10.83x | 0.31% | 39.13B | |
| Weighted average by Cap. | 22.21x | 32.04x | 13.52x | 0.42% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- AVTX Stock
- Valuation Avalo Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
